Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma

Cancer Research
Lotte SpelMarianne Boes

Abstract

: Neuroblastoma is the second most common tumor in children. The cause of neuroblastoma is thought to lie in aberrant development of embryonic neural crest cells and is accompanied by low MHC-1 expression and suppression of the NF-κB transcription factor, thereby gearing cells toward escape from immunosurveillance. Here, we assess regulation of the MHC-1 gene in neuroblastoma to enhance its immunogenic potential for therapeutic T-cell targeting. A genome-wide CRISPR screen identified N4BP1 and TNIP1 as inhibitory factors of NF-κB-mediated MHC-1 expression in neuroblastoma. Patients with advanced stage neuroblastoma who expressed high levels of TNIP1 and N4BP1 exhibited worse overall survival. Depletion of N4BP1 or TNIP1 increased NF-κB and MHC-1 expression and stimulated recognition by antigen-specific CD8+ T cells. We confirmed that TNIP1 inhibited canonical NF-κB member RelA by preventing activation of the RelA/p50 NF-κB dimer. Furthermore, N4BP1 inhibited both canonical and noncanonical NF-κB through binding of deubiquitinating enzyme CEZANNE, resulting in stabilization of TRAF3 and degradation of NF-κB-inducing kinase NIK. These data suggest that N4BP1/CEZANNE or TNIP1 may be candidate targets for immunotherapy in neuroblas...Continue Reading

References

Oct 16, 1999·The Journal of Biological Chemistry·Z Feng, A G Porter
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·A SerranoF Garrido
Oct 27, 2001·The Journal of Biological Chemistry·X BianA W Opipari
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·André OberthuerMatthias Fischer
Sep 28, 2004·Cancer Immunology, Immunotherapy : CII·Matthias WölflFrank Berthold
Jun 1, 2005·Cancer Letters·Lizzia RaffaghelloVito Pistoia
May 11, 2006·The Journal of Biological Chemistry·Claudio MauroAntonio Leonardi
Oct 5, 2006·International Journal of Cancer. Journal International Du Cancer·Joannes F M JacobsI Jolanda M de Vries
Dec 21, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina M CoughlinRobert H Vonderheide
Jan 12, 2007·Apoptosis : an International Journal on Programmed Cell Death·Jane L ArmstrongPenny E Lovat
Jun 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrew OberstGerry Melino
Mar 6, 2009·Genome Biology·Ben LangmeadSteven L Salzberg
Mar 17, 2009·Biochimica Et Biophysica Acta·Beau J FennerJochen H M Prehn
Aug 22, 2009·Biochemical and Biophysical Research Communications·Shai CohenShirly Lahav-Baratz
Feb 27, 2010·The Journal of Biological Chemistry·Pradeep BistaMatvey E Lukashev
Jun 19, 2010·The New England Journal of Medicine·John M Maris
Dec 21, 2010·Oncogene·M M ChaturvediB B Aggarwal
Jun 11, 2011·Nature Reviews. Immunology·Hans HäckerMichael Karin
Oct 6, 2011·Seminars in Cancer Biology·Robert C Seeger
Dec 31, 2011·Genes & Cancer·Thomas D Gilmore, Steve Gerondakis
Jan 18, 2012·Seminars in Pediatric Surgery·Andrew M Davidoff
May 25, 2013·Nature Reviews. Cancer·Nai-Kong V Cheung, Michael A Dyer
Jul 31, 2014·Nature Methods·Neville E SanjanaFeng Zhang
Oct 11, 2014·Nucleic Acids Research·Eva K BrinkmanBas van Steensel
Nov 12, 2014·Annual Review of Medicine·Chrystal U Louis, Jason M Shohet
Dec 4, 2014·Molecular Neurobiology·Matheus Augusto de Bittencourt PasqualiJosé Cláudio Fonseca Moreira
Dec 18, 2014·Genome Biology·Michael I LoveSimon Anders
Mar 26, 2015·Immunotherapy·Michela CroceSilvano Ferrini
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Dec 19, 2015·Nature Communications·Najim AmezianeJosephine C Dorsman
Jan 13, 2016·British Journal of Cancer·Jill E HunterNeil D Perkins
Jun 28, 2016·Nature Methods·Stefka TyanovaJürgen Cox

❮ Previous
Next ❯

Citations

May 17, 2019·Immunotherapy·Parnian JabbariNima Rezaei
Dec 27, 2019·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Annelisa M CornelStefan Nierkens
Jul 20, 2019·Biomolecules·Ridvan NepravishtaElena Santonico
Dec 24, 2019·Frontiers in Oncology·Jian-Guo ZhouUdo S Gaipl
Apr 11, 2020·Biomolecules·Elena Santonico
Aug 27, 2019·Biochimica Et Biophysica Acta. Reviews on Cancer·Ji ChengWenyi Wei
Dec 21, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Judith WienkeJan J Molenaar
Nov 28, 2020·Advanced Biosystems·Zexu Li, Teng Fei
Mar 4, 2021·Nature Communications·Hexin ShiBruce Beutler
Feb 17, 2021·Cancer Discovery·Shengqing Stan GuX Shirley Liu
Jun 4, 2021·Molecular Immunology·M L M JongsmaR M Spaapen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.